CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Joaquin Duato

CEO & Chairman, Johnson & Johnson

Search every verified Joaquin Duato interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Joaquin Duato, chairman and CEO of Johnson & Johnson, spoke during the company's third-quarter 2026 earnings call on October 14, 2026, reporting operational sales growth of 6% and highlighting sequential improvement from the second quarter. He said the company expects further acceleration in 2027 and a path to double-digit growth by the end of the decade, citing drivers in innovative medicine such as Darzalex, Tremfya, Rybrevant, and Erleada, as well as MedTech opportunities in cardiovascular devices, Impella, and the Ottava robotic surgery platform. Duato also noted that oncology sales grew approximately 17% in the quarter and that eight brands achieved double-digit growth. Duato described Johnson & Johnson as "one of the cleanest growth stories in health care" and stated that the company's six strategic focus areas—oncology, immunology, neuroscience, cardiovascular, surgery, and vision—target areas of high unmet need. He indicated that the company's growth outlook does not assume any inorganic additions, though it remains open to strategic opportunities that complement its portfolio. Duato said further details on the company's pipeline would be provided at an enterprise business review in December 2026.

Recent appearances

Notable quotes

“We are always trying to price our medicines in a way that is consistent with the benefit they bring. In this country, we have to we can work in different areas in order to improve affordability. One area is trying to trying to take some of the the the the percentage that the middleman get uh in pharmaceuticals try to get back to the to the to the patient. We can also we should be doing that. We can also have other co”

“My principle, our principle as a company is the more people that has health coverage the better for this country. So, anything that improves health coverage and more people covered the better for this country. It's important for a country as rich as the US that we have healthcare extended to as many people as possible.”

“We are just at the beginning. This is just the initial innings of a cycle of growth for Johnson & Johnson. We were saying that we have line of sight to double-digit growth by the end of the decade. And that's remarkable for a company which is more than a hundred billion dollars. And you know why? We are not a one-trick pony company. We have a whole stable of medicines and medical devices. We have 28 platforms of more”

“It's going up. You know, as a matter of fact, last year in 2025 was one of the best years for Johnson & Johnson history in terms of total shareholder return. We had 47% return in 2025.”

“When the credo has short-term interference with economic issues, we always we always look for the long term. Because ultimately, over the long term, you need to be able to balance the interest of all the stakeholders and always putting the patient first.”

Other executives at Johnson & Johnson

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →